About Us
Candesant’s mission is to offer an uncomplicated, effective alternative to current therapies to improve the lives of people who sweat too much. All 84 million of them¹.
Candesant Biomedical
Candesant Biomedical is focused on development of a novel treatment for the non-invasive treatment of excessive sweating or hyperhidrosis.
The company’s lead product is a topical patch to conveniently treat excessive sweating with a quick, in-office procedure.
Two successful clinical studies demonstrated efficacy in reducing sweat and validated that the energy is reproducibly generated, highly targeted and appears to inactivate the most active sweat glands.
In these initial clinical studies, Candesant’s treatment demonstrated significant sweat reduction benefits lasting up to 3-4 months after a single, no down-time treatment.
Leadership
Candesant is led by a deeply experienced team of drug and device development professionals passionate about meeting real patient and physician needs.
Niquette Hunt
Founder and CEO
Niqui has over 25 years experience in developing, launching and commercially scaling 20+ products.
Read More
Niquette Hunt
Founder and CEO
Niqui has over 25 years experience in developing, launching and commercially scaling 20+ products in both large corporations (P&G, Warner Lambert) and early stage companies across multiple verticals in the consumer medicine market. Every business she managed has increased sales, profits and/or market share. Prior to Candesant, she led the commercial strategy at Revance Therapeutics and helped raise over $250M in the company’s 2014 IPO and follow-on financing.
Mary Beth Kreissler
Chief Financial Officer
Mary Beth has 20 years’ experience with pre-revenue and early commercialization stage companies in tech and life sciences.
Read More
Mary Beth Kreissler
Chief Financial Officer
Mary Beth has 20 years’ experience with pre-revenue and early commercialization stage companies in tech and life sciences. She previously helped launch and lead finance for Willow Pump, SmartThings, Qatalyst Partners and Quinstreet. She began her career with PricewaterhouseCoopers.
Angela Boyd
Chief Commercial Officer
Angela has more than 25 years experience developing and launching products in the dermatology/aesthetics space.
Read More
Angela Boyd
Chief Commerical Officer
Angela has more than 25 years experience developing and launching products in the dermatology/aesthetics space.
Erica Bazerkanian
SVP Marketing
Erica Bazerkanian has 25 years’ experience in commercial strategy, new product development and market creation.
Read More
Erica Bazerkanian
SVP Marketing
Erica Bazerkanian has 25 years’ experience in commercial strategy, new product development and market creation, including 15 years in medical aesthetics at companies such as Kythera Biopharmaceuticals and Revance Therapeutics. Most recently she served as vice president, aesthetics and therapeutics marketing for Revance Therapeutics, leading pre-commercialization efforts for the company’s aesthetic and therapeutic botulinum toxin portfolio.
Jesse Rosen
VP Product Development
Jesse has 20+ years of experience in the design, development and manufacturing of medical devices.
Read More
Jesse Rosen
VP Product Development
Jesse has 20+ years of experience in the design, development and manufacturing of medical devices. He was an early employee at Zeltiq as well as head of product development at Myoscience.
Erin Tims
VP Clinical Affairs
Erin has 15 years experience in the design and execution of clinical studies across various therapeutic categories.
Read More
Erin Tims
VP Clinical Affairs
Erin has 15 years experience in the design and execution of clinical studies across various therapeutic categories. She has successfully overseen the regulatory approval process for both multi-national corporations and start-ups.
Scott Wilson
Head, Regulatory Affairs
Scott has over 25 years' experience in the medical device industry, specializing in regulatory affairs and quality.
Read More
Scott Wilson
Head, Regulatory Affairs
Scott has over 25 years' experience in the medical device industry, specializing in regulatory affairs and quality. He has contributed to the success of both venture funded and commercial stage companies developing novel therapies.
In Remembrance
Jacob Waugh, MD
Co-Founder, Inventor of the TAT Technology
Jacob Waugh, a prolific inventor who left behind 40+ issued and 300+ pending patents, dedicated his life to scientific innovation and development.
Read More
Jacob Waugh, MD
Co-Founder, Inventor of the TAT Technology
Jacob Waugh dedicated his life to scientific innovation and development. He was a gifted physician, scientist, entrepreneur and educator. Jacob was a pioneer in in-vivo tissue engineering at Stanford Medical Center. Prior to Candesant, he was the co-founder, chief scientific officer and medical director of Revance Therapeutics. He was a prolific inventor and leaves behind 40+ issued and 300+ pending patents. He will be deeply missed.
Board of Directors
Samara Braunstein
Samara Braunstein is a marketing and financial professional with decades of experience in healthcare, consumer products, and finance.
Read More
Samara Braunstein
Sam’s extensive industry knowledge stems from past roles in the M&A group at Credit Suisse, as a deal professional at GTCR, and as a senior member of portfolio companies for Lightyear Capital and The Carlyle Group. Sam also served on the Board of Directors for Higher One Holdings (NYSE:ONE) through its acquisition by a Providence Equity subsidiary. She served until recently as the Chief Revenue Officer of Concertiv, which provides outsourced operations and technologies to over 50 financial institutions. Sam leverages her diverse experience in sales and marketing gained from her work as Director of Interactive marketing at AOL and from her work in brand management at Pfizer (Warner Lambert), where she worked on initiatives such as the launch of Zantac 75 OTC, which generated more than $150 million in year one sales. Sam was CEO and founder of Wellgate Products and led the company to #4 market share in the U.S. prior to its acquisition by Church & Dwight Co., Inc.
Eric Compton
Eric Compton is a seasoned executive and business leader with a proven track record of success in the Medical Device, Diagnostics and Consumer Packaged Goods industries.
Read More
Eric Compton
Eric Compton is a seasoned executive and business leader with a proven track record of success in the Medical Device, Diagnostics and Consumer Packaged Goods industries. With over 35 years of experience, Eric has had various leadership roles in multibillion dollar companies including President, Chief Operating Officer and CEO. Eric currently serves as Executive in Residence at Villanova University in the School of Business and as a consultant to both Private Equity and Venture Capital firms. Prior to being an Executive in Residence, Eric was the CEO at Z-Medica, a Linden Capital Company, which was sold to Teleflex for over $525 million. Throughout his career, Eric has demonstrated a commitment to excellence, innovation, and ethical leadership. He has consistently shown a keen ability to navigate complex business challenges and drive sustainable growth. Eric holds a BA degree in Economics and Speech Communications from the University of Richmond and an MBA from Kennesaw State University. He has also started the Compton Scholarship at Villanova University for financially challenged students from the Philadelphia area. Outside of his professional life, Eric enjoys time at Bethany Beach where he can be seen DJing at local restaurants, crabbing on his boat or playing pickleball. He is also a published author with his most recent fictional work a short story in “Beach Holidays”, Cat & Mouse Press, 2022.
Brad Hauser
Brad Hauser is a seasoned aesthetics leader with experience managing R&D, operations and commercial teams.
Read More
Brad Hauser
Brad Hauser is a seasoned aesthetics leader with experience managing R&D, operations and commercial teams. Over the last 20 years, he has assisted in the development and launch of many of the most well-known brands in the aesthetic device industry and successfully transacted and integrated several businesses into both small and large companies. He is currently Chief Product Officer at the Beauty Health Company (Nasdaq: SKIN). Previously, Brad led Soliton, Inc. (Nasdaq: SOLY), as President and CEO, from a clinical-stage start-up through FDA clearance and acquisition by Allergan Aesthetics, an AbbVie company, for $550M enterprise value in 2021. Prior to Soliton, he helped build the CoolSculpting franchise, within Zeltiq Aesthetics, from a $100M to over $350M+ global business over 4 years and sale to Allergan for $2.4B in 2017. He graduated from Stanford University with a degree in Human Biology and concentration in sports medicine.
Niquette Hunt
Niqui has over 25 years experience in developing, launching and commercially scaling 20+ products.
Read More
Niquette Hunt
Niqui has over 25 years experience in developing, launching and commercially scaling 20+ products in both large corporations (P&G, Warner Lambert) and early stage companies across multiple verticals in the consumer medicine market. Every business she managed has increased sales, profits and/or market share. Prior to Candesant, she led the commercial strategy at Revance Therapeutics and helped raise over $250M in the company’s 2014 IPO and follow-on financing.
Michael Kane, MD
Michael Kane, MD is an aesthetic plastic surgeon and entrepreneur who has been practicing in New York City for more than 25 years.
Read More
Michael Kane, MD
Michael is an aesthetic plastic surgeon and entrepreneur who has been practicing in New York City for more than 25 years. Dr. Kane performs a wide variety of cutting-edge cosmetic surgical procedures, facial rejuvenation, and cosmetic injections. Dr. Kane has been in private practice since 1992 and frequently lectures on topics relating to aesthetic plastic surgery and aesthetic medicine. Dr. Kane completed his college and medical school studies in only five years at the combined Pennsylvania State University/Jefferson Medical College program. At Jefferson, Dr. Kane was a member of the Hobart Hare Honor Society. Dr. Kane completed a general surgery residency at New York Medical College and then a plastic surgical residency at Wright State University, Dr. Kane then completed an additional fellowship in aesthetic surgery at New York University, based at the Manhattan Eye, Ear & Throat Hospital. Dr. Kane is known for his work with botulinum toxin A. He pioneered the use of Botulinum for cosmetic purposes while a fellow at the Manhattan Eye, Ear & Throat Hospital. Over the past 25 years, Dr. Kane has taught thousands of physicians how to properly inject botulinum toxin and fillers through lectures and live demonstrations. Dr. Kane is also an authority on correcting the tear trough and periorbital area using fillers. He authored the first scientific paper on this technique, and continues to lecture worldwide on the subject. Dr. Kane has over one thousand scientific presentations around the globe. His original work has appeared in Plastic and Reconstructive Surgery, the Aesthetic Surgery Journal, Aesthetic Plastic Surgery, Dermatologic Surgery, the Journal of Drugs in Dermatology, the Journal of Cosmetic Laser Therapy, Facial Plastic Surgery, and Ophthalmic Plastic and Reconstructive Surgery. He launched the award-winning Serum Savant skin care line in 2015. He serves as a consultant to nearly all of the major aesthetics companies. He has written many textbook chapters and three books.
Ellie McGuire
Ellie McGuire is a partner of the LS Polaris Innovation Fund. McGuire currently serves on the Boards of Montis Biosciences and Mellitus.
Read More
Ellie McGuire
Ellie McGuire is a partner of the LS Polaris Innovation Fund. McGuire currently serves on the Boards of Montis Biosciences and Mellitus. In addition she was the founding President of Volastra Therapeutics and currently acts as CEO of Boston based Mellitus. She is an expert in residence for the Harvard Office of Technology Development and is on the Fred Hutch Evergreen Fund Advisory Committee. Prior to co-founding the LS Polaris Innovation Fund, McGuire was the Head of Business Development at Lyndra, where she was a member of the founding team. She previously held leadership and consulting positions in business development, operations, and strategy in multiple life science companies including Arsia Therapeutics, Lyndra, and XTuit Pharmaceuticals.
Susan Stimson
With over 25 years’ experience in the medical device and pharmaceutical sectors, Susan is an accomplished executive in development and commercialization of new medical technologies at both start-ups and large public companies.
Read More
Susan Stimson
With over 25 years’ experience in the medical device and pharmaceutical sectors, Susan is an accomplished executive in development and commercialization of new medical technologies at both start-ups and large public companies.
She currently serves as Managing Director at KCK, a leading venture capital and growth equity investment firm and serves on the Board of Directors for several medical device companies.
Prior to KCK, Susan served as President & CEO of Zenflow, a company dedicated to less invasive treatment of enlarged prostate and remains as Executive Director on the company’s Board of Directors. Her unique expertise includes serving as Chief Strategy Officer for Intersect ENT, building the company from its inception into a high growth public company (NYSE: XENT). There she devised and executed its product, commercial and long-term strategies to result in a portfolio of products with over $100M in sales and an eventual sale to Medtronic for over $1B.
She is a proud Guidant alumnus working in roles of increasing responsibility in Vascular Intervention and Cardiac Rhythm Management divisions, was an executive at one of the first structural heart repair companies, is a frequent speaker on the medtech industry and is a founding Member of MedtechWomen, a not-for profit dedicated to developing and promoting female executives. Susan holds a B.S. in Biomedical Engineering from Marquette University, Milwaukee, Wisconsin.